Share this article
Share this article
WILLINGTON, England, May 10, 2021 /PRNewswire/ Bionical Emas, a global specialist Clinical Research Organization (CRO), has today announced the launch of a U.S. Expanded Access Program for Jazz Pharmaceuticals investigational therapy JZP458 (asparaginase
Erwinia chrysanthemi (recombinant)) for the treatment of adult and pediatric patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) following hypersensitivity or silent inactivation to
E. coli-derived asparaginases. JZP458 is currently under FDA review for marketing authorization in the United States. The Expanded Access Program (EAP) provides a mechanism to fulfill unsolicited physician requests in the U.S. and support the special need of a patient.